Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

C1425000

Chloramphenicol sodium succinate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Chloramphenicol succinate sodium salt, Chloramphenicol α-succinate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
C15H15Cl2N2O8Na
Numéro CAS:
982-57-0
Poids moléculaire :
445.18
Numéro MDL:
MFCD00079025
Code UNSPSC :
41116107
ID de substance PubChem :
329774883
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

chloramphenicol

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

[Na].O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)N(=O)=O

InChI

1S/C15H16Cl2N2O8.Na.H/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26;;/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21);;/t10-,13-;;/m1../s1

Clé InChI

RJOAHMNSYANTPN-OWVUFADGSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Chloramphenicol sodium succinate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

C1200000

Chloramphénicol, European Pharmacopoeia (EP) Reference Standard

C1400000

Chloramphenicol palmitate isomer, European Pharmacopoeia (EP) Reference Standard

C1300000

Chloramphenicol dipalmitate, European Pharmacopoeia (EP) Reference Standard

C1350000

Chloramphenicol disodium disuccinate, European Pharmacopoeia (EP) Reference Standard

PHR1412

Chloramphenicol, Pharmaceutical Secondary Standard; Certified Reference Material

1107004

Chloramphénicol, United States Pharmacopeia (USP) Reference Standard

1107300

Chloramphenicol palmitate, United States Pharmacopeia (USP) Reference Standard

1107401

Chloramphenicol palmitate, United States Pharmacopeia (USP) Reference Standard

1107503

Chloramphenicol palmitate, United States Pharmacopeia (USP) Reference Standard

BP854

Chloramphénicol, British Pharmacopoeia (BP) Reference Standard

BP1061

Chloramphenicol sodium succinate, British Pharmacopoeia (BP) Reference Standard

BP417

2-Amino-1-(4-nitrophenyl)propane-1,3-diol, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H351

Classification des risques

Acute Tox. 4 Oral - Carc. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J A Turton et al.
International journal of experimental pathology, 83(5), 225-238 (2003-03-19)
In man, chloramphenicol (CAP), induces two major haemotoxic effects. First, a reversible, dose-related reticulocytopenia and anaemia developing during treatment. Second, a non-dose-related aplastic anaemia (AA), developing weeks after treatment, is often irreversible and fatal. In previous studies, we developed a
C S Ambekar et al.
European journal of clinical pharmacology, 56(5), 405-409 (2000-09-29)
The metabolism of chloramphenicol succinate (CAPS) by human bone marrow was studied in vitro using 75 marrow samples. Whole marrow samples were incubated with CAPS with or without reduced nicotinamide adenine dinucleotide phosphate for 1, 2 and 3 h at
Roberta A Gottlieb et al.
Autophagy, 7(4), 434-435 (2010-12-29)
Interventions that reduce infarct size in animal models have largely failed to improve outcome in patients suffering acute myocardial infarction (MI), or 'heart attack'. Our group recently reported a reduction of infarct size by chloramphenicol treatment in a porcine in
M F Festing et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 39(4), 375-383 (2001-04-11)
Much toxicological research continues to be done using genetically undefined "outbred" stocks of mice and rats, although the case for using isogenic strains has been made repeatedly in the literature over a period of more than two decades. Also, very
D E Holt et al.
Human & experimental toxicology, 17(1), 8-17 (1998-03-10)
1. Chloramphenicol continues to be widely used in many parts of the world despite its known haematotoxicity. Until now, elucidation of the mechanisms involved and any attempt at amelioration of the toxic effects have been hampered by the lack of
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique